Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.

Tong L, Ding N, Tong X, Li J, Zhang Y, Wang X, Xu X, Ye M, Li C, Wu X, Bao H, Zhang X, Hong Q, Song Y, Shao YW, Bai C, Zhou J, Hu J.

Theranostics. 2019 Jul 28;9(19):5532-5541. doi: 10.7150/thno.34070. eCollection 2019.

2.

Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma.

Song Z, Cai Z, Yan J, Shao YW, Zhang Y.

Transl Lung Cancer Res. 2019 Aug;8(4):392-400. doi: 10.21037/tlcr.2019.08.14.

3.

[The study of pleural effusion supernatant cell-free tumor DNA in tumor mutational burden assessment of advanced lung cancer].

Tong L, Ding N, Li JM, Xu XB, Zhang Y, Ye MS, Li C, Zhang X, Hong QY, Zhou J, Bai CX, Hu J.

Zhonghua Jie He He Hu Xi Za Zhi. 2019 Aug 12;42(8):596-601. doi: 10.3760/cma.j.issn.1001-0939.2019.08.007. Chinese.

PMID:
31378021
4.

Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.

Ohira T, Sakai K, Matsubayashi J, Kajiwara N, Kakihana M, Hagiwara M, Hibi M, Yoshida K, Maeda J, Ohtani K, Nagao T, Nishio K, Ikeda N.

Cancer Sci. 2016 Nov;107(11):1660-1666. doi: 10.1111/cas.13068.

5.

Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.

Stasik S, Salomo K, Heberling U, Froehner M, Sommer U, Baretton GB, Ehninger G, Wirth MP, Thiede C, Fuessel S.

Clin Biochem. 2019 Feb;64:60-63. doi: 10.1016/j.clinbiochem.2018.11.009. Epub 2018 Dec 4.

PMID:
30528938
6.

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.

Kim ST, Lee WS, Lanman RB, Mortimer S, Zill OA, Kim KM, Jang KT, Kim SH, Park SH, Park JO, Park YS, Lim HY, Eltoukhy H, Kang WK, Lee WY, Kim HC, Park K, Lee J, Talasaz A.

Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465.

7.

A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients.

Xu H, Baidoo AAH, Su S, Ye J, Chen C, Xie Y, Bertolaccini L, Ismail M, Ricciuti B, Ng CSH, Flores RM, Li Y; written on behalf of AME Lung Cancer Collaborative Group.

Transl Lung Cancer Res. 2019 Apr;8(2):135-143. doi: 10.21037/tlcr.2019.03.10.

8.
9.

Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.

Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M.

Oncologist. 2019 Mar 22. pii: theoncologist.2018-0572. doi: 10.1634/theoncologist.2018-0572. [Epub ahead of print]

PMID:
30902917
10.

Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.

Beije N, Helmijr JC, Weerts MJA, Beaufort CM, Wiggin M, Marziali A, Verhoef C, Sleijfer S, Jansen MPHM, Martens JWM.

Mol Oncol. 2016 Dec;10(10):1575-1584. doi: 10.1016/j.molonc.2016.10.001.

11.

[Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer].

Zhang R, Li Y, Chen Y, Liu X, Wang Z, Sun H, Zheng Y, Ding Z, Lan L, Li M, Qin J, Chen X.

Zhonghua Yi Xue Za Zhi. 2015 Dec 15;95(47):3839-42. Chinese.

PMID:
27337801
12.

A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients.

Kawahara A, Fukumitsu C, Azuma K, Taira T, Abe H, Takase Y, Murata K, Sadashima E, Hattori S, Naito Y, Akiba J.

Cytopathology. 2018 Apr;29(2):150-155. doi: 10.1111/cyt.12517. Epub 2018 Jan 24.

PMID:
29363841
13.

Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.

Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, Girard N, Trédaniel J, Guilleminault L, Gervais R, Prim N, Vincent M, Margery J, Larivé S, Foucher P, Duvert B, Vallee M, Le Calvez-Kelm F, McKay J, Missy P, Morin F, Zalcman G, Olivier M, Souquet PJ; BioCAST/IFCT-1002 investigators.

Clin Cancer Res. 2014 Sep 1;20(17):4613-24. doi: 10.1158/1078-0432.CCR-13-3063. Epub 2014 Jul 10.

14.

Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.

Wu Z, Yang Z, Li CS, Zhao W, Liang ZX, Dai Y, Zhu Q, Miao KL, Cui DH, Chen LA.

Cancer Med. 2019 Mar;8(3):910-919. doi: 10.1002/cam4.1935. Epub 2019 Feb 14.

15.

Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.

Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y.

Oncologist. 2016 Feb;21(2):156-64. doi: 10.1634/theoncologist.2015-0288. Epub 2016 Jan 14.

16.

The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.

Yang Y, Shen X, Li R, Shen J, Zhang H, Yu L, Liu B, Wang L.

Oncotarget. 2017 Jul 25;8(30):49773-49782. doi: 10.18632/oncotarget.17937.

17.

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.

Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS.

Oncologist. 2016 Jun;21(6):684-91. doi: 10.1634/theoncologist.2016-0030. Epub 2016 May 5.

18.

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors.

Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Medeiros LJ, Wistuba II, Luthra R.

Oncotarget. 2017 Oct 24;9(12):10259-10271. doi: 10.18632/oncotarget.21982. eCollection 2018 Feb 13.

19.

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.

Iwama E, Sakai K, Azuma K, Harada T, Harada D, Nosaki K, Hotta K, Ohyanagi F, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Ann Oncol. 2017 Jan 1;28(1):136-141. doi: 10.1093/annonc/mdw531.

PMID:
28177428
20.

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.

Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F.

Clin Cancer Res. 2018 Jan 1;24(1):181-188. doi: 10.1158/1078-0432.CCR-17-2007. Epub 2017 Oct 19.

Supplemental Content

Support Center